Abstract: Scores for particular network models (those having a source node connected to a set of measurable downstream nodes via causal edges) are computed across multiple networks by accounting for an overlap between these models in a manner that reduces cross-network redundancy and increases the specificity of the network models for the network in which they are found. According to another aspect, a meta-network model is created for networks by accounting for the occurrence of network models that are found in multiple networks in a manner that reduces the redundancy across networks and that increases the specificity of the network model score. Preferably, this process provides additional weighting factors for each node in the network model.

Abstract: Scores for particular network models (those having a source node connected to a set of measurable downstream nodes via causal edges) are computed across multiple networks by accounting for an overlap between these models in a manner that reduces cross-network redundancy and increases the specificity of the network models for the network in which they are found. According to another aspect, a meta-network model is created for networks by accounting for the occurrence of network models that are found in multiple networks in a manner that reduces the redundancy across networks and that increases the specificity of the network model score. Preferably, this process provides additional weighting factors for each node in the network model.

Abstract: To directly compare two or more network perturbation amplitude scores and identify whether the difference between them is meaningful, an Uncertainty (confidence interval) for each of the scores is computed. According to this disclosure, experimental replicates of the measurements are used to compute the score Uncertainty, based on an assumption that variability between measurement replicates represents a largest source of error in the score. Preferably, at least three (3) experimental replicates for both treated and control conditions are used to compute Uncertainty.

Abstract: In the US about ? of college women show evidence of HPV infection. The clinical problem may be even larger in developing countries. There are currently no effective therapies for HPV infections, aside from therapeutic cone biopsies, which often are followed by recurrent, progressive lesions. Thus, pharmaceutical compositions and processes for treatment of an HPV infection are detailed. In particular, a pharmaceutical composition for inhibiting growth of a human papilloma virus-infected cell is provided which includes a peptide halomethyl ketone inhibitor of a chymotrypsin or chymotrypsin-like protease and a pharmaceutically acceptable carrier. A preferred inhibitor is AAPFcmk.

Abstract: In the US about ? of college women show evidence of HPV infection. The clinical problem may be even larger in developing countries. There are currently no effective therapies for HPV infections, aside from therapeutic cone biopsies, which often are followed by recurrent, progressive lesions. Thus, pharmaceutical compositions and processes for treatment of an HPV infection are detailed. In particular, a pharmaceutical composition for inhibiting growth of a human papilloma virus-infected cell is provided which includes a peptide halomethyl ketone inhibitor of a chymotrypsin or chymotrypsin-like protease and a pharmaceutically acceptable carrier. A preferred inhibitor is AAPFcmk.